Skip to main content
. 2019 May 30;29(8):572–581. doi: 10.1093/glycob/cwz039

Fig. 6.

Fig. 6

Heparin oligosaccharide products treated with heparanase Bp. Low sulfated domain will be cut by heparanase Bp and form a highly sulfated domain, which has a GlcA residue at the non-reducing end, and it cannot be IdoA/IdoA2S/GlcA2S, and GlcN at the reducing end, which can be modified to GlcNAc/GlcNAc6S/GlcNS, and it cannot be GlcNS6S/GlcNS6S3S.